MARKET

HSKA

HSKA

Heska
NASDAQ

Real-time Quotes | Nasdaq Last Sale

248.67
-12.19
-4.67%
After Hours: 249.75 +1.08 +0.43% 19:08 09/20 EDT
OPEN
254.44
PREV CLOSE
260.86
HIGH
257.84
LOW
245.54
VOLUME
40.96K
TURNOVER
--
52 WEEK HIGH
275.94
52 WEEK LOW
93.90
MARKET CAP
2.65B
P/E (TTM)
-1475.7864
1D
5D
1M
3M
1Y
5Y
CNBC PRO Talks: Star small-cap manager Amy Zhang unveils her top stock picks
Amy Zhang, portfolio manager of the Alger Small Cap Focus, Small Cap Growth and Mid Cap Focus strategies and Mid Cap 40 ETF, joins CNBC's Brian Sullivan to discuss the state of the small and mid-cap market, and the rationale for some of her top picks.
CNBC.com · 09/01 19:49
Invesco Main Street Small Cap Fund Buys Heska Corp, The Honest Co Inc, Amyris Inc, Sells ...
GuruFocus News · 09/01 18:38
Insider Trends: Selling By Insiders Lingers at Heska Corp
MT Newswires · 08/19 15:52
Motley Fool Asset Management LLC Buys Atlassian Corporation PLC, Mastercard Inc, Medtronic PLC, ...
GuruFocus News · 08/16 19:38
Should You Consider Investing in Heska Corporation (HSKA)?
Alger, an investment management firm, published its “Alger Small Cap Focus Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. During the quarter, the largest portfolio sector weightings were Health Care and Information Tech...
Insider Monkey · 08/12 17:06
Heska Corp (HSKA) EVP, CFO Catherine Grassman Sold $1.3 million of Shares
GuruFocus News · 08/09 10:38
--JPMorgan Adjusts Price Target on Heska to $300 From $275, Maintains Overweight Rating
MT Newswires · 08/04 11:52
--Piper Sandler Adjusts Heska's Price Target to $305 From $240, Reiterates Overweight Rating
MT Newswires · 08/04 10:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSKA. Analyze the recent business situations of Heska through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSKA stock price target is 282.50 with a high estimate of 310.00 and a low estimate of 225.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 11.71M
% Owned: 110.02%
Shares Outstanding: 10.65M
TypeInstitutionsShares
Increased
70
883.72K
New
22
75.72K
Decreased
60
484.98K
Sold Out
26
257.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.45%
Healthcare Equipment & Supplies
-1.59%
Key Executives
Non-Executive Chairman/Independent Director
Scott Humphrey
President/Chief Executive Officer/Director
Kevin Wilson
Chief Financial Officer/Executive Vice President
Catherine Grassman
Chief Operating Officer/Executive Vice President
Nancy Wisnewski
Executive Vice President/Chief Administrative Officer/General Counsel/Secretary
Christopher Sveen
Executive Vice President
Eleanor Baker
Executive Vice President
Steven Eyl
Executive Vice President
Anthony Providenti
Independent Director
Robert Antin
Independent Director
Stephen Davis
Independent Director
Mark Furlong
Independent Director
Joachim Hasenmaier
Independent Director
Sharon Larson
Independent Director
David Sveen
Declaration Date
Dividend Per Share
Ex-Div Date
09/12/2012
Dividend USD 0.1
09/26/2012
05/07/2012
Dividend USD 0.1
06/27/2012
02/22/2012
Dividend USD 0.1
03/28/2012
About HSKA
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.

Webull offers kinds of Heska Corp stock information, including NASDAQ:HSKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSKA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSKA stock methods without spending real money on the virtual paper trading platform.